These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16363279)

  • 1. The response of skin perfusion and of rheological and immunological variables to intravenous prostanoid administration in Raynaud's phenomenon secondary to collagenosis.
    Drinda S; Neumann T; Pöhlmann G; Vogelsang H; Stein G; Wolf G; Hein G
    Vasa; 2005 Nov; 34(4):243-9. PubMed ID: 16363279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laser Doppler-recorded venoarteriolar reflex in Raynaud's phenomenon.
    Stoyneva Z
    Auton Neurosci; 2004 Nov; 116(1-2):62-8. PubMed ID: 15556839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.
    Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H
    Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E; Virgilio S; Ghirardi R; Martinelli M
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon.
    Marasini B; Massarotti M; Bottasso B; Coppola R; Del Papa N; Maglione W; Comina DP; Maioli C
    Scand J Rheumatol; 2004; 33(4):253-6. PubMed ID: 15370722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon.
    Kyle MV; Belcher G; Hazleman BL
    J Rheumatol; 1992 Sep; 19(9):1403-6. PubMed ID: 1279169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postocclusive reactive hyperemia in hand-arm vibration syndrome.
    Stoyneva Z
    Int J Occup Med Environ Health; 2016; 29(4):659-66. PubMed ID: 27443761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial.
    Tucker AT; Pearson RM; Cooke ED; Benjamin N
    Lancet; 1999 Nov; 354(9191):1670-5. PubMed ID: 10568568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local cold exposure test with a new arterial photoplethysmographic sensor in healthy controls and patients with secondary Raynaud's phenomenon.
    Hahn M; Hahn C; Jünger M; Steins A; Zuder D; Klyscz T; Büchtemann A; Rassner G; Blazek V
    Microvasc Res; 1999 Mar; 57(2):187-98. PubMed ID: 10049666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laser-Doppler measurement of digital blood flow regulation in normals and in patients with Raynaud's phenomenon.
    Kristensen JK; Engelhart M; Nielsen T
    Acta Derm Venereol; 1983; 63(1):43-7. PubMed ID: 6191488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The influence of isosorbide mononitrate on skin blood flow in patients with Raynaud's syndrome].
    Gross R; Galus K; Zajac S; Jedrasik M
    Wiad Lek; 2002; 55(1-2):29-34. PubMed ID: 12043312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microcirculatory and clinical effects of serial percutaneous application of carbon dioxide in primary and secondary Raynaud's phenomenon.
    Schmidt J; Monnet P; Normand B; Fabry R
    Vasa; 2005 May; 34(2):93-100. PubMed ID: 15968890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases].
    Kumagai S; Morinobu A; Ozaki S; Nakao K; Ishida H
    Ryumachi; 1998 Jun; 38(3):504-10. PubMed ID: 9721558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Raynaud's phenomenon and blood viscosity].
    Lacombe C; Mouthon JM; Bucherer C; Lelievre JC; Bletry O; Godeau P
    J Mal Vasc; 1992; 17 Suppl B():132-5. PubMed ID: 1602250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue.
    Yardumian DA; Isenberg DA; Rustin M; Belcher G; Snaith ML; Dowd PM; Machin SJ
    Br J Rheumatol; 1988 Jun; 27(3):220-6. PubMed ID: 2454140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.